{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:44:42Z","timestamp":1792025082060,"version":"4.4.0"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:00:00Z","timestamp":1770681600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010724","name":"Health System Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010724","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["valuehealthregionalissues.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health Regional Issues"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.vhri.2026.101601","type":"journal-article","created":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T01:54:45Z","timestamp":1773453285000},"page":"101601","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Cost-Utility and Budget Impact Analysis of Tumor Necrosis Factor-Alpha Inhibitors for the Treatment of Refractory Nonsystemic Juvenile Idiopathic Arthritis in Thailand"],"prefix":"10.1016","volume":"56","author":[{"given":"Nitichen","family":"Kittiratchakool","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chanida","family":"Ekakkararungroj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soamarat","family":"Vilaiyuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sirirat","family":"Charuvanij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parichat","family":"Khaosut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Butsabong","family":"Lerkvaleekul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maynart","family":"Sukharomana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarin","family":"K.C.","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pritaporn","family":"Kingkaew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vhri.2026.101601_bib1","series-title":"Juvenile idiopathic arthritis","author":"Thatayatikom","year":"2023"},{"issue":"6","key":"10.1016\/j.vhri.2026.101601_bib2","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1002\/acr.23870","article-title":"American College of Rheumatology\/Arthritis Foundation guideline for the treatment of juvenile idiopathic arthritis: therapeutic approaches for non-systemic polyarthritis, sacroiliitis, and enthesitis","volume":"71","author":"Ringold","year":"2019","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"2","key":"10.1016\/j.vhri.2026.101601_bib3","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jbspin.2013.09.003","article-title":"Prevalence and incidence of juvenile idiopathic arthritis: a systematic review","volume":"81","author":"Thierry","year":"2014","journal-title":"Jt Bone Spine"},{"issue":"12","key":"10.1016\/j.vhri.2026.101601_bib4","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1111\/1756-185X.12637","article-title":"A retrospective study on 158 Thai patients with juvenile idiopathic arthritis followed in a single center over a 15-year period","volume":"19","author":"Vilaiyuk","year":"2016","journal-title":"Int J Rheum Dis"},{"issue":"165","key":"10.1016\/j.vhri.2026.101601_bib5","first-page":"1","article-title":"Announcement: national list of essential medicines B.E. 2564","volume":"138","year":"2021","journal-title":"R Thai Gov Gaz"},{"issue":"13","key":"10.1016\/j.vhri.2026.101601_bib6","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1001\/jama.294.13.1671","article-title":"Medical treatment of juvenile idiopathic arthritis","volume":"294","author":"Hashkes","year":"2005","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.vhri.2026.101601_bib7","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s12969-023-00852-5","article-title":"Disability and disease-related damage in Thai children and adolescents with juvenile idiopathic arthritis","volume":"21","author":"Tangcheewinsirikul","year":"2023","journal-title":"Pediatr Rheumatol Online J"},{"issue":"2","key":"10.1016\/j.vhri.2026.101601_bib10","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1093\/rheumatology\/key306","article-title":"Use and effectiveness of rituximab in children and young people with juvenile idiopathic arthritis in a cohort study in the United Kingdom","volume":"58","author":"Kearsley-Fleet","year":"2018","journal-title":"Rheumatology (Oxford, England)"},{"key":"10.1016\/j.vhri.2026.101601_bib11","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.jpeds.2018.08.065","article-title":"Risk of serious infections associated with biologic agents in juvenile idiopathic arthritis: a systematic review and meta-analyses","volume":"204","author":"Aeschlimann","year":"2019","journal-title":"J Pediatr"},{"key":"10.1016\/j.vhri.2026.101601_bib12","author":"Ekakkararungroj"},{"key":"10.1016\/j.vhri.2026.101601_bib13","author":"Kulpokin"},{"issue":"34","key":"10.1016\/j.vhri.2026.101601_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta20340","article-title":"The clinical effectiveness and cost-effectiveness of abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis: a systematic review and economic evaluation","volume":"20","author":"Shepherd","year":"2016","journal-title":"Health Technol Assess"},{"issue":"Suppl 5","key":"10.1016\/j.vhri.2026.101601_bib15","first-page":"S4","article-title":"Guidelines for health technology assessment in Thailand (second edition)-the development process","volume":"97","author":"Chaikledkaew","year":"2014","journal-title":"J Med Assoc Thai Chotmaihet Thangphaet"},{"key":"10.1016\/j.vhri.2026.101601_bib16","series-title":"Health Technology Assessment Guideline for Thailand","article-title":"Working group for the development of the health technology assessment guideline for Thailand 2021","year":"2021"},{"key":"10.1016\/j.vhri.2026.101601_bib17","series-title":"Nonthaburi: Health Intervention and Technology Assessment Program (HITAP)","author":"Perez","year":"2012"},{"key":"10.1016\/j.vhri.2026.101601_bib18","series-title":"Meeting minutes: Health Economic Working Group 5\/2020","author":"Prawjaeng","year":"2020"},{"key":"10.1016\/j.vhri.2026.101601_bib19","series-title":"Meeting minutes: Health Economic Working Group 1\/2021","author":"Prawjaeng","year":"2021"},{"key":"10.1016\/j.vhri.2026.101601_bib20","series-title":"Meeting minutes: Health Economic Working Group 2\/2022","author":"Prasertsakul","year":"2022"},{"issue":"1","key":"10.1016\/j.vhri.2026.101601_bib21","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jval.2021.11.1351","article-title":"Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022 statement): updated reporting guidance for health economic evaluations","volume":"25","author":"Husereau","year":"2022","journal-title":"Value Health"},{"key":"10.1016\/j.vhri.2026.101601_bib22","series-title":"Guideline for Growth Assessment in Thai Children (in Thai). Nonthaburi: Bureau of Nutrition (BoN)","author":"Chittchang","year":"2000"},{"issue":"11","key":"10.1016\/j.vhri.2026.101601_bib23","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1093\/rheumatology\/ket150","article-title":"Recent developments in disease activity indices and outcome measures for juvenile idiopathic arthritis","volume":"52","author":"McErlane","year":"2013","journal-title":"Rheumatology (Oxford, England)"},{"issue":"2","key":"10.1016\/j.vhri.2026.101601_bib24","first-page":"390","article-title":"International League of Associations for Rheumatology Classification of Juvenile Idiopathic Arthritis","volume":"31","author":"Petty","year":"2004","journal-title":"Edmonton, 2001"},{"issue":"2","key":"10.1016\/j.vhri.2026.101601_bib25","doi-asserted-by":"crossref","first-page":"190","DOI":"10.3899\/jrheum.180168","article-title":"Toward new classification criteria for juvenile idiopathic arthritis: first steps, Pediatric Rheumatology International Trials Organization international consensus","volume":"46","author":"Martini","year":"2019","journal-title":"J Rheumatol"},{"issue":"7","key":"10.1016\/j.vhri.2026.101601_bib26","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1002\/1529-0131(199707)40:7<1202::AID-ART3>3.0.CO;2-R","article-title":"Preliminary definition of improvement in juvenile arthritis","volume":"40","author":"Giannini","year":"1997","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.vhri.2026.101601_bib27","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1186\/s13075-016-1170-3","article-title":"Comparison of treatment response, remission rate and drug adherence in polyarticular juvenile idiopathic arthritis patients treated with etanercept, adalimumab or tocilizumab","volume":"18","author":"Horneff","year":"2016","journal-title":"Arthritis Res Ther"},{"issue":"11","key":"10.1016\/j.vhri.2026.101601_bib28","first-page":"2290","article-title":"Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis","volume":"31","author":"Wallace","year":"2004","journal-title":"J Rheumatol"},{"issue":"8","key":"10.1016\/j.vhri.2026.101601_bib29","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa0706290","article-title":"Adalimumab with or without methotrexate in juvenile rheumatoid arthritis","volume":"359","author":"Lovell","year":"2008","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.vhri.2026.101601_bib30","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1136\/annrheumdis-2018-213902","article-title":"Treat to target (drug-free) inactive disease in DMARD-naive juvenile idiopathic arthritis: 24-month clinical outcomes of a three-armed randomised trial","volume":"78","author":"Hissink Muller","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.vhri.2026.101601_bib31","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1136\/ard.2010.143347","article-title":"Aggressive combination drug therapy in very early polyarticular juvenile idiopathic arthritis (ACUTE-JIA): a multicentre randomised open-label clinical trial","volume":"70","author":"Tynjala","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.vhri.2026.101601_bib32","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1136\/annrheumdis-2016-210456","article-title":"Subcutaneous golimumab for children with active polyarticular-course juvenile idiopathic arthritis: results of a multicentre, double-blind, randomised-withdrawal trial","volume":"77","author":"Brunner","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.vhri.2026.101601_bib33","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-037588","article-title":"Cost-utility and budget impact analysis of tocilizumab for the treatment of refractory systemic juvenile idiopathic arthritis in Thailand","volume":"10","author":"Kittiratchakool","year":"2020","journal-title":"BMJ Open"},{"key":"10.1016\/j.vhri.2026.101601_bib34","series-title":"Compilation of Rules, Regulations, Announcements, and Guidelines Related to the Management of Subsidies for Private Schools","first-page":"17","article-title":"Regulation of the Ministry of Education on measures to assist students in private schools with individual subsidies (No. 3) B.E.2560","year":"2022"},{"issue":"9","key":"10.1016\/j.vhri.2026.101601_bib35","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0162478","article-title":"Estimation of disability weights in the general population of South Korea using a paired comparison","volume":"11","author":"Ock","year":"2016","journal-title":"PLOS One"},{"issue":"9","key":"10.1016\/j.vhri.2026.101601_bib36","first-page":"1989","article-title":"Disease course and outcome of juvenile rheumatoid arthritis in a multicenter cohort","volume":"29","author":"Oen","year":"2002","journal-title":"J Rheumatol"},{"issue":"5","key":"10.1016\/j.vhri.2026.101601_bib40","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1177\/0272989X211001859","article-title":"Valuation survey of EQ-5D-Y based on the international common protocol: development of a value set in Japan","volume":"41","author":"Shiroiwa","year":"2021","journal-title":"Med Decis Mak"},{"issue":"4","key":"10.1016\/j.vhri.2026.101601_bib41","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S2352-4642(19)30027-6","article-title":"Phenotypic variability and disparities in treatment and outcomes of childhood arthritis throughout the world: an observational cohort study","volume":"3","author":"Consolaro","year":"2019","journal-title":"Lancet Child Adolesc Health"},{"issue":"10","key":"10.1016\/j.vhri.2026.101601_bib42","first-page":"2055","article-title":"HLA-B27 predicts a more extended disease with increasing age at onset in boys with juvenile idiopathic arthritis","volume":"35","author":"Berntson","year":"2008","journal-title":"J Rheumatol"},{"issue":"5","key":"10.1016\/j.vhri.2026.101601_bib43","doi-asserted-by":"crossref","first-page":"725","DOI":"10.3899\/jrheum.121257","article-title":"HLA-B27 predicts a more chronic disease course in an 8-year followup cohort of patients with juvenile idiopathic arthritis","volume":"40","author":"Berntson","year":"2013","journal-title":"J Rheumatol"},{"issue":"1","key":"10.1016\/j.vhri.2026.101601_bib44","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12969-019-0363-0","article-title":"Enthesitis-related arthritis is the most common category of juvenile idiopathic arthritis in Taiwan and presents persistent active disease","volume":"17","author":"Shih","year":"2019","journal-title":"Pediatr Rheumatol Online J"},{"issue":"1","key":"10.1016\/j.vhri.2026.101601_bib45","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s12969-021-00498-1","article-title":"Delivery of paediatric rheumatology care: a survey of current clinical practice in Southeast Asia and Asia-Pacific regions","volume":"19","author":"Tangcheewinsirikul","year":"2021","journal-title":"Pediatr Rheumatol Online J"},{"issue":"17","key":"10.1016\/j.vhri.2026.101601_bib46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta6170","article-title":"A systematic review of effectiveness and economic evaluation of new drug treatments for juvenile idiopathic arthritis: etanercept","volume":"6","author":"Cummins","year":"2002","journal-title":"Health Technol Assess"},{"issue":"1","key":"10.1016\/j.vhri.2026.101601_bib47","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/acr.20337","article-title":"Cost-effectiveness of biologics in polyarticular-course juvenile idiopathic arthritis patients unresponsive to disease-modifying antirheumatic drugs","volume":"63","author":"Ungar","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"12","key":"10.1016\/j.vhri.2026.101601_bib48","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1002\/acr.22903","article-title":"Cost-effectiveness analysis of first-line treatment with biologic agents in polyarticular juvenile idiopathic arthritis","volume":"68","author":"Luca","year":"2016","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"9","key":"10.1016\/j.vhri.2026.101601_bib50","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.3899\/jrheum.120089","article-title":"Access to biologic therapies in Canada for children with juvenile idiopathic arthritis","volume":"39","author":"Leblanc","year":"2012","journal-title":"J Rheumatol"},{"key":"10.1016\/j.vhri.2026.101601_bib51","series-title":"World Health Organization Model List of Essential Medicines for Children: 7th list","year":"2019"},{"issue":"1","key":"10.1016\/j.vhri.2026.101601_bib52","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1093\/rheumatology\/keq292","article-title":"Complete control of disease activity and remission induced by treatment with etanercept in juvenile idiopathic arthritis","volume":"50","author":"Papsdorf","year":"2011","journal-title":"Rheumatology (Oxford, England)"},{"issue":"10","key":"10.1016\/j.vhri.2026.101601_bib53","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1080\/14712598.2022.2105140","article-title":"Comparison of the outcomes between early and late anti-tumor necrosis factor therapy in patients with enthesitis-related subcategory of juvenile idiopathic arthritis: a multi-center study in Southeast Asia","volume":"22","author":"Vilaiyuk","year":"2022","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.vhri.2026.101601_bib55","author":"Kittiratchakool"},{"issue":"1","key":"10.1016\/j.vhri.2026.101601_bib56","doi-asserted-by":"crossref","first-page":"2011:53","DOI":"10.3390\/pharmaceutics3010053","article-title":"Factors and mechanisms for pharmacokinetic differences between pediatric population and adults","volume":"3","author":"Fernandez","year":"2011","journal-title":"Pharmaceutics"},{"issue":"2","key":"10.1016\/j.vhri.2026.101601_bib57","first-page":"110","article-title":"Use of medicines in children: pharmacological and practical issues","volume":"11","author":"Shashikant","year":"2023","journal-title":"J Pharm Care"}],"container-title":["Value in Health Regional Issues"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212109926000154?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212109926000154?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T23:56:57Z","timestamp":1792022217000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212109926000154"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":50,"alternative-id":["S2212109926000154"],"URL":"https:\/\/doi.org\/10.1016\/j.vhri.2026.101601","relation":{},"ISSN":["2212-1099"],"issn-type":[{"value":"2212-1099","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-Utility and Budget Impact Analysis of Tumor Necrosis Factor-Alpha Inhibitors for the Treatment of Refractory Nonsystemic Juvenile Idiopathic Arthritis in Thailand","name":"articletitle","label":"Article Title"},{"value":"Value in Health Regional Issues","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vhri.2026.101601","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of International Society for Pharmacoeconomics and Outcomes Research, Inc.","name":"copyright","label":"Copyright"}],"article-number":"101601"}}